Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | TAS2R14 | Q9NYV8 | 8/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1734017 | 0.75 | IDO1 (0.61) | MEN1ALDH1A1KMT2AL3MBTL1KDM4E | |
| SCHEMBL13113121 | 0.75 | MEN1 (0.66) | MEN1ALDH1A1KMT2AL3MBTL1TAS2R14 | |
| SCHEMBL20552535 | 0.74 | PLK1 (0.59) | MEN1ALDH1A1KMT2AL3MBTL1TAS2R14 | |
| SCHEMBL29888967 | 0.74 | PLK1 (0.59) | MEN1ALDH1A1KMT2AL3MBTL1TAS2R14 | |
| SCHEMBL27021634 | 0.72 | ALDH1A1 (0.56) | MEN1ALDH1A1KMT2AL3MBTL1KDM4E | |
| SCHEMBL30740388 | 0.71 | DHODH (0.36) | ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL31419367 | 0.70 | ALDH1A1 (0.53) | MEN1ALDH1A1KMT2AL3MBTL1KDM4E | |
| SCHEMBL20552659 | 0.69 | DHODH (0.53) | TAS2R14IDO1CASP6 | |
| SCHEMBL31324840 | 0.68 | KDM4E (0.61) | MEN1ALDH1A1KMT2AL3MBTL1KDM4E | |
| SCHEMBL14262602 | 0.68 | MEN1 (0.73) | MEN1ALDH1A1KMT2AL3MBTL1TAS2R14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9446012-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-09-20 | — | — | US | disclosed |
| EP-2027091-B1 | NEW PHARMACEUTICAL COMPOUNDS | BIAL PORTELA & CA SA (PT) | 2016-01-06 | — | — | EP | disclosed |
| US-20140024682-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & CA, S.A. (PT) | 2014-01-23 | — | — | US | disclosed |
| US-8536203-B2 | Pharmaceutical compounds | BIAL-PORTELA & CA, S.A. (PT) | 2013-09-17 | — | — | US | disclosed |
| EP-2617713-A1 | New Pharmaceutical Compounds | BIAL - Portela & Ca., S.A. (PT) | 2013-07-24 | — | — | EP | disclosed |
| CN-101454285-B | Oxadiazole derivatives as comt inhibitors | PORTELA & CA SA | 2012-06-27 | — | — | CN | disclosed |
| US-20100168113-A1 | Pharmaceutical Compounds | BIAL-PORTELA & CA., S.A. (PT) | 2010-07-01 | — | — | US | disclosed |
| CN-101454285-A | Oxadiazole derivatives as comt inhibitors | PORTELA & CA SA (PT) | 2009-06-10 | — | — | CN | disclosed |
| EP-2027091-A1 | NEW PHARMACEUTICAL COMPOUNDS | BIAL - Portela & Ca., S.A. (PT) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007117165-A1 | NEW PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & CA, S.A. (PT) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168113-A1 | Pharmaceutical Compounds | PMP22, CNR2, OPRL1 | MEN1 3595/4885ALDH1A1 1070/4885KMT2A 3356/4885 |
| US-20140024682-A1 | PHARMACEUTICAL COMPOUNDS | PMP22, CNR2, OPRL1 | MEN1 3595/4885ALDH1A1 1070/4885KMT2A 3356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.